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Various biological responses stimulated by insulin
have been thought to be regulated by phosphatidylinosi-
tol 3-kinase, including glucose transport, glycogen syn-
thesis, and protein synthesis. However, the molecular
link between phosphatidylinositol 3-kinase and these
biological responses has been poorly understood. Re-
cently, it has been shown that protein kinase B (PKB/c-
Akt/Rac) lies immediately downstream from phosphati-
dylinositol 3-kinase. Here, we show that expression of a
constitutively active form of PKB induced glucose up-
take, glycogen synthesis, and protein synthesis in L6
myotubes downstream of phosphatidylinositol 3-kinase
and independent of Ras and mitogen-activated protein
kinase activation. Introduction of constitutively active
PKB induced glucose uptake and protein synthesis but
not glycogen synthesis in 3T3L-1 adipocytes, which lack
expression of glycogen synthase kinase 3 different from
L6 myotubes. Furthermore, we show that deactivation
of glycogen synthase kinase 3 and activation of rapamy-
cin-sensitive serine/threonine kinase by PKB in L6 myo-
tubes might be involved in the enhancement of glycogen
synthesis and protein synthesis, respectively. These re-
sults suggest that PKB acts as a key enzyme linking
phosphatidylinositol 3-kinase activation to multiple bi-
ological functions of insulin through regulation of
downstream kinases in skeletal muscle, a major target
tissue of insulin.
Insulin promotes a wide variety of biological responses in
vivo, including regulation of glucose metabolism and protein
synthesis (1, 2). One of the most important metabolic responses
by insulin is the stimulation of facilitated glucose transport in
muscle and adipose tissues, primarily due to translocation of
glucose transporter isoform 4 (GLUT4) from an intracellular
pool to the plasma membrane (3, 4). Another major aspect of
the glucose metabolism regulated by insulin is the activation of
glycogen synthesis through the activation of glycogen synthase
(GS)1 in skeletal muscle (5–8). Insulin also serves as the major
regulator of protein synthesis by phosphorylation of eukaryotic
initiation factor 4E (eIF-4E)-binding protein 1 (4E-BP1) and its
dissociation from eIF-4E, thereby increasing the eIF-4E avail-
able for initiation of mRNA translation (9, 10). Many processes
of these biological actions in response to insulin have been
demonstrated to be regulated by phosphatidylinositol 3-kinase
(PI3-K) (11–17). However, the molecular link between PI3-K
activation and final biological functions is unknown. Recent
reports revealed that protein kinase B (PKB) is regulated by
PI3-K through the direct interaction of its pleckstrin homology
domain and the phosphorylated products of PI3-K, leading to
phosphorylation in its serine/threonine residues and activation
by a putative upstream kinase (18–23). Moreover, PKB has
been shown to phosphorylate and inhibit glycogen synthase
kinase 3 (GSK3) in vitro (24), suggesting the possibility that it
might be involved in glycogen synthesis regulated by PI3-K.
Nevertheless, expression of a constitutively active form of PKB
failed to stimulate glycogen synthesis in 3T3L-1 adipocytes,
although it enhanced glucose transport activity (25). These
findings prompted us to study the roles of PKB in multiple
biological responses of insulin. Here, we show that expression
of GagPKB (18), a constitutive active form of PKB, promotes
glucose transport activity and protein synthesis rate in both
3T3L-1 adipocytes and L6 myotubes, which are demonstrated
to be regulated by PI3-K, independent of mitogen-activated
protein kinase. We also show that expression of GagPKB pro-
motes glycogen synthesis in L6 myotubes but not in 3T3L-1
adipocytes that lack expression of GSK3. These data suggest
that PKB might be a key player in insulin-stimulated multiple
metabolic actions in skeletal muscles.
EXPERIMENTAL PROCEDURES
Cell Culture and Adenovirus-mediated Gene Transfer—3T3L-1 cells
and L6 cells were maintained in Dulbecco’s modified Eagle’s medium
(DMEM) and induced to differentiate into adipocytes and myotubes as
described in Refs. 26 and 27, respectively. The differentiated cells were
cultured in media containing the adenoviruses for 1 h at 37 °C, and
DMEM supplemented with fetal calf serum was added and cultured for
24 h. One day later, when cells were subjected to assays, they were
serum-starved for 20 h. The adenoviruses were applied at a concentra-
tion of 3 3 108 plaque-forming units/cm2 dish. Under these conditions,
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and L6 cells on postinfection from day 1 through day 3 measured by
b-galactosidase assay. Expression of GagPKB was confirmed by West-
ern blot analysis and immune complex kinase assay as described below.
Expression of dominant negative Ras (DNRas) and that of mitogen-
activated protein kinase (MAPK) were confirmed by measurement of
MAPK activity in response to insulin as described (28). Insulin-induced
MAPK activity was completely inhibited in cells expressing DNRas and
increased 5–8-fold in cells expressing MAPK compared with that in
cells expressing LacZ.
Recombinant Adenoviruses—cDNA of GagPKB was constructed as
described (18). cDNA of DNRas (K-Ras substituted Ser-17 to Asn by
polymerase chain reaction method) was kindly provided by Dr. Takai
(Osaka University). cDNA of MAPK was constructed as described (28).
cDNA of GSK3a (29) was kindly provided by Dr. He (NCI, National
Institutes of Health) and fused to hemagglutinin (HA) epitope sequence
substituted for its original stop codon (GSK3a-HA). cDNA fragments
including the whole coding region of GagPKB, DNRas, MAPK, and
GSK3a-HA were introduced to the expression cosmid cassette with
blunt end ligation into the SwaI site, respectively, as described (30).
The recombinant adenoviruses, Adex1CAGagPKB, Adex1CADNRas,
Adex1CAMAPK, and Adex1CAGSK3a-HA were constructed by homol-
ogous recombination between the expression cosmid cassette and pa-
rental virus genome as described (30). The control adenovirus
Adex1CALacZ and the cosmid cassette were kindly provided by Dr.
Saito (University of Tokyo).
Antibodies—Rabbit polyclonal anti-PKB antibodies (aPKB-CT) were
generated against a peptide corresponding to the sequence of 465–480
human PKB (Upstate Biotechnology Inc.). Rabbit polyclonal anti-p70
S6 kinase antibodies (C-18) were generated against a peptide corre-
sponding to the sequence of 485–502 of rat p70 S6 kinase (Santa Cruz
Biotechnology). Anti-PP1G antibodies were generated against a peptide
corresponding to the sequence surrounding site 1 of rabbit skeletal
muscle PP1G (SPQPSRRGSESSEE) as described (31). Rabbit poly-
clonal anti-GSK3 antibodies (aGSK3) were generated against a peptide
corresponding to the sequence of 462–475 of rat GSK3a, as described
(32). GSK3b monoclonal antibodies were generated by immunizing
against the N-terminal region (1–160) of rat GSK3b (Transduction
Laboratory). Monoclonal anti-HA antibodies (12CA5) were generated
against a peptide (YPYDVPDYA) corresponding to the sequence of
influenza hemagglutinin (Boehringer Mannheim). Rabbit polyclonal
anti-4E-BP1 antibodies were generated against a glutathione S-trans-
ferase 4E-BP1 fusion protein (33). Immunoprecipitations were per-
formed as described below. Immunoblots were developed using the
chemiluminescence Western blotting kit (Boehringer Mannheim) and
subjected to autoradiography.
In Vitro Kinase Assays—Cells were starved for 20 h, treated without
or with insulin, and lysed with the lysis buffer containing 20 mM
Tris-HCl, pH 7.5, 25 mM b-glycerophosphate, 100 mM NaCl, 1 mM
sodium orthovanadate, 2 mM EGTA, 5 mg/ml leupeptin, 5 mg/ml apro-
tinin, and 1 mM phenylmethylsulfonyl fluoride. Cell lysates were sub-
jected to immunoprecipitation with aPKB-CT, C-18, or aGSK3 followed
by PKB kinase assay as described (Cross et al. (24, 42)), S6 kinase assay
as described (14), or GSK3 kinase assay. Briefly, in PKB and S6 kinase
assays, the immunoprecipitates with aPKB-CT or C-18 were washed
and resuspended in 50 mM Tris-HCl, pH 7.5, 10 mM MgCl2, 1 mM
dithiotreitol to which 50 mM ATP, 3 mCi of [g32P]ATP, and 1 mg of
cross-tide in PKB assay or 1 mg of S6 peptide (32-mer peptide from the
C-terminal sequence of ribosomal S6 protein; Life Technologies Inc.) in
S6 kinase assay had been added. After 20 min at 30 °C, the reaction was
stopped, and the aliquots were spotted on squares of P-81 paper,
washed, and counted by Cherenkov. GSK3 kinase activity was deter-
mined by the method as described (34) with modification. The immu-
noprecipitates with aGSK3 were resuspended in 25 mM b-glycerophos-
phate, 40 mM HEPES, pH 7.2, 10 mM MgCl2, and 2 mM protein kinase
inhibitor adding 50 mM ATP, 5 mCi of [g32P]ATP, and 1 mg of phospho-
glycogen synthase peptide (Upstate Biotechnology Inc.). After 20 min at
30 °C, the reaction was stopped, and the aliquots were spotted on
squares of P-81 paper, washed, and counted by Cherenkov.
2-Deoxyglucose (2-DG) Uptake Assays—2-Deoxyglucose (2-DG) up-
take assays were performed as described (26, 27) with modification.
Cells were grown in 12-well plates and infected with adenoviruses as
described above. Before initiating glucose uptake assays, cells were
washed three times with phosphate-buffered saline and incubated in 1
ml of serum-free DMEM for 3 h at 37 °C. Next, cells were washed once
with Krebs-Ringer phosphate-HEPES buffer (KRHB) containing 130
mM NaCl, 5 mM KCl, 1.3 mM CaCl2, 1.3 mM MgSO4, 10 mM Na2HPO4,
and 25 mM HEPES, pH 7.4, and incubated in 1 ml of KRHB containing
0.1% bovine serum albumin without or with 100 nM insulin for 20 min
at 37 °C. Glucose uptake was initiated by the addition of 2-deoxy-D-[2,6-
3H]glucose to a final concentration of 0.5 mCi for 5 min at 37 °C and
terminated by two washes with ice-cold KRHB. Cells were solubilized
with 0.4 ml of 0.1% SDS and counted by scintillation counter. Nonspe-
cific glucose uptake was measured in the presence of 20 mM cytochalasin
B and 200 mM phloretin and was subtracted from total uptake in each
assay to obtain specific uptake.
Glycogen Synthase Assays—Glycogen synthase activity was meas-
ured as described previously (14) with slight modifications. Cells were
infected with adenoviruses as described above and incubated in serum-
free DMEM for 20 h. Then they were washed twice and incubated with
KRHB without or with 100 nM insulin for 20 min. Cells were lysed with
lysis buffer containing 25 mM Tris-HCl, pH 7.0, 30% glycerol, 10 mM
EDTA, 100 mM KF, 1 mM phenylmethylsulfonyl fluoride. The lysates
were centrifuged, and 30 ml of the supernatant was added to 60 ml of the
assay mixture containing 50 mM Tris-HCl, pH 7.4, 25 mM NaF, 20 mM
EDTA, 1 mg/ml glycogen, and 0.1 mCi of UDP-[14C]glucose and with
0.25 or 10 mM glucose 6-phosphate. After incubation at 30 °C for 30 min,
aliquots were spotted on 3MM paper (Whatman), washed four times
with ice-cold 70% ethanol, and counted radioactivity by scintillation
counter.
Assays of Protein Synthesis Rate—The protein synthesis rate was
determined by measuring the incorporation of [3H]tyrosine into protein
as described (35, 36). Briefly, cells were grown in 6-well dishes and
infected with adenoviruses as described above. After starvation in se-
rum-free DMEM for 20 h, cells were incubated in 1 ml of serum-free
F-12 (Hams’) medium without or with 100 nM insulin for 1 h. Then, the
medium was replaced with medium containing the same additions plus
L-[2,3,5,6-3H]tyrosine (5 mCi/ml). After 1 h, cells were rinsed twice with
ice-cold phosphate-buffered saline and extracted with 1 ml of buffer
containing 10 mM Tris-HCl, pH 7.5, 250 mM KCl, 10 mM MgCl2, 6 mM
2-mercaptothanol, 1 mM phenylmethylsulfonyl fluoride before centrifu-
gation. For measurement of radioactivity in total soluble protein, ali-
quots of the supernatants (30 mg of protein) were spotted on 3MM paper
strips, and the strips were kept in boiling 10% trichloroacetic acid for 5
min, washed, and the radioactivity was counted.
RESULTS AND DISCUSSION
Expression of GagPKB in 3T3L-1 Adipocytes and L6 Myo-
tubes—We investigated insulin-sensitive cell lines, 3T3L-1 adi-
pocytes and L6 myotubes expressing the constitutively active
form of PKB (GagPKB) using adenovirus vector (30). Western
blot analysis revealed that the amount of GagPKB expressed
was comparable to that of endogenous PKB (Fig. 1A). PKB
activity, assessed as the ability to phosphorylate Crosstide, a
peptide corresponding to the sequence surrounding the phos-
phorylation site Ser-21 in GSK3a (24), was 2–3-fold higher at
the basal state in cells expressing GagPKB than in control cells
expressing LacZ. In fact, basal PKB activity in cells expressing
GagPKB was already comparable to that detected in control
cells after insulin stimulation (Fig. 1B). Increase in PKB activ-
ity was maintained significantly higher after insulin stimula-
tion in cells expressing GagPKB as compared with control cells.
Concomitantly, p70 S6 kinase activity in cells expressing Gag-
PKB was increased in both basal and insulin-stimulated states
in these cell lines (Fig. 1C). In cells expressing LacZ, pretreat-
ment with wortmannin, which completely inhibited PI3-K, also
completely inhibited the insulin-induced activation of endoge-
nous PKB (Fig. 1B). In cells expressing GagPKB, however,
PKB activity was still about 2-fold higher than that in cells
expressing LacZ at the basal state without wortmannin,
whereas an increase in the kinase activity by insulin stimula-
tion was not noted (Fig. 1B). Although not statistically signif-
icant, it was noted that wortmannin treatment reduced PKB
activity in both cells expressing LacZ and GagPKB in 3T3L-1
adipocytes and L6 myotubes, suggesting the involvement of
wortmannin-sensitive pathway in the PKB activation even in
the basal condition. Neither expression of DNRas or MAPK nor
treatment with PD98059 (MAP kinase kinase inhibitor) af-
fected PKB or p70 S6 kinase activity in either of the cell lines
(data not shown), although Ras has been reported to be in-
volved in activation of PKB in some cell lines (19).
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Activation of PKB Mimics Insulin-induced Glucose Trans-
port Activity Regulated by PI3-K both in 3T3L-1 Adipocytes and
L6 Myotubes—Expression of GagPKB induced 2-DG uptake in
the absence of insulin in 3T3L-1 adipocytes to almost the same
levels as detected after insulin treatment of cells expressing
LacZ (Fig. 2A). This is consistent with the recent results using
FIG. 1. Expression of GagPKB by adenovirus-mediated gene transfer increases PKB and S6 kinase activity in 3T3L-1 adipocytes
and L6 myotubes. A, expression levels of endogenous PKB and GagPKB in cells expressing the indicated constructs. Cells were cultured and
infected with adenoviruses as described under “Experimental Procedures,” then lysed and subjected to SDS-polyacrylamide gel electrophoresis
(10% gel) followed by Western blotting with the antibodies against the C-terminal region of PKB (aPKB-CT). B, in vitro kinase assays of PKB
immunoprecipitated from serum-starved 3T3L-1 cells or L6 cells expressing the indicated constructs. Serum-starved cells were pretreated without
or with wortmannin (30 nM) for 30 min before insulin stimulation. After cells were treated without or with 100 nM insulin for 5 min, they were
subjected to immunoprecipitation with aPKB-CT followed by immune complex kinase assay. C, in vivo activation of p70 S6 kinase by expression
of GagPKB in 3T3L-1 cells or L6 cells. Serum-starved cells were treated without or with 100 nM insulin for 30 min and subjected to immunopre-
cipitation with the antibodies against p70 S6 kinase (C-18) followed by immune complex kinase assay toward S6 peptide (KEAKEKRQE-
QIAKRRRLSSLRASTSKSGGSQK). The results in B and C are expressed as the ratio to the value of untreated cells expressing LacZ. Each bar
represents the mean 6 S.E. of more than three independent experiments.
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another type of constitutively active PKB in 3T3L-1 adipocytes
(25) and the findings that expression of GagPKB promotes
GLUT4 appearance at the cell surface in isolated adipocytes
(37). In L6 myotubes, expression of GagPKB also induced fun-
damentally similar effects (Fig. 2B). Pretreatment with wort-
mannin, which completely inhibited both PI3-K and insulin-
sensitive endogenous PKB (Fig. 1B), also completely inhibited
2-DG uptake stimulated by insulin in 3T3L-1 adipocytes and
L6 myotubes expressing LacZ (Fig. 2, A and B). In cells ex-
pressing GagPKB treated with wortmannin, basal 2-DG up-
take was still higher than that in 3T3L-1 adipocytes and L6
myotubes expressing LacZ, although insulin stimulation was
not noted (Fig. 2, A and B). This was consistent with the results
that GagPKB was constitutively active even after wortmannin
treatment to the same extent as PKB activity after insulin
stimulation in cells expressing LacZ (Fig. 1B). In addition,
expression of neither DNRas nor MAPK affected 2-DG uptake
(Fig. 2, A and B), indicating that the Ras/MAPK pathway is
neither sufficient nor required for glucose uptake by insulin in
these cell lines. These findings suggest that PKB activated by
insulin via PI3-K might stimulate glucose transport activity
independent of Ras/MAPK activation in skeletal muscle and
adipose tissue, the major tissues for glucose disposal by insulin.
Activation of PKB Mimics Insulin-induced Glycogen Synthe-
sis Regulated by PI3-K in L6 Myotubes but Not in 3T3L-1
Adipocytes—Next, we investigated GS activity regulating gly-
cogen synthesis, a major glucose utilization pathway by insu-
lin. In 3T3L-1 adipocytes, expression of GagPKB did not affect
either basal or insulin-stimulated GS activity (Fig. 3A),
whereas inhibition of PI3-K by wortmannin resulted in com-
plete inhibition of insulin-dependent GS activity in cells ex-
pressing either LacZ or GagPKB (Fig. 3A). Moreover, expres-
sion of neither DNRas nor MAPK affected GS activity (Fig. 3A).
These results suggest that a PI3-K-dependent but PKB-inde-
pendent pathway plays a key role in activation of GS activity in
3T3L-1 adipocytes. In contrast, expression of GagPKB in L6
myotubes enhanced basal GS activity to essentially the same
levels as the insulin-stimulated activity in cells expressing
LacZ. Increase in insulin-stimulated activity in cells expressing
GagPKB compared with cells expressing LacZ did not reach
statistical significance (Fig. 3B). After treatment with wort-
mannin in L6 myotubes, GS activity in cells expressing Gag-
PKB still remained significantly higher than that in cells ex-
pressing LacZ (Fig. 3B), suggesting that wortmannin inhibited
FIG. 2. Expression of GagPKB en-
hances glucose transport activity in
3T3L-1 adipocytes and L6 myotubes.
A, 2-DG uptake activity in 3T3L-1 adipo-
cytes expressing the indicated constructs.
Serum-starved cells were cultured in glu-
cose-free KRHB and pretreated without
or with wortmannin (30 nM) for 30 min
before insulin stimulation. After cells
were treated without or with 100 nM in-
sulin for 10 min, the assays were per-
formed in 3T3L-1 adipocytes as described
under “Experimental Procedures.” The
2-DG uptake in untreated 3T3L-1 cells
expressing LacZ was 0.13 6 0.02 nmol/
min/5 3 105 cells. B, 2-DG uptake activity
in L6 myotubes expressing the indicated
constructs. Cells were treated as de-
scribed above, and the assays were per-
formed as described under “Experimental
Procedures.” The 2-DG uptake in un-
treated L6 cells expressing LacZ was
0.07 6 0.01 nmol/min/5 3 105 cells. The
results in A and B are expressed as the
ratio to the value of untreated cells ex-
pressing LacZ. Each bar represents the
mean 6 S.E. of more than three independ-
ent experiments.
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both PI3-K and the insulin-induced activation of endogenous
PKB but that constitutively active GagPKB could mimic PI3-
K-dependent GS activation in L6 myotubes. In L6 myotubes as
well as 3T3L-1 adipocytes, expression of neither DNRas nor
MAPK affected GS activity (Fig. 3B). These findings indicate
that constitutively active PKB is sufficient to stimulate GS
activity in L6 myotubes and that the Ras/MAPK pathway is not
involved in GS activation.
Activation of PKB Inhibits GSK3 Activity in L6 Myotubes—
What is it that causes the difference between 3T3 L-1 adipo-
cytes and L6 myotubes? GS activation by insulin is thought to
be mediated by promotion of dephosphorylation and activation
of GS due to either activation of protein phosphatase 1 by
phosphorylation of its G subunit (PP1G) (6, 38, 39) or inacti-
vation of GSK3 by phosphorylation (8, 24, 40) or both. We
addressed the possibility that the difference in the relative
abundance of PP1G and GSK3 between 3T3L-1 adipocytes and
L6 myotubes might lead to alterations of the predominant
signaling pathways regulating GS activity by insulin. Thus, we
investigated the expression levels of PP1G and GSK3 by West-
ern blot and compared the two cell lines. Fig. 3C shows that
PP1G was expressed in both 3T3L-1 adipocytes and L6 myo-
tubes and seemed to be more abundant in the former. In con-
trast, expression of GSK3 (both a and b) was observed only in
L6 myotubes but not in differentiated 3T3L-1 adipocytes as
described previously (41). These findings raise the possibility
that PKB might stimulate GS activity by inactivation of GSK3
in L6 myotubes, and this mechanism might not work in 3T3L-1
adipocytes. In fact, expression of GagPKB significantly inhib-
ited GSK3 activity at the basal state to essentially the same
levels as insulin-stimulated GSK3 activity in cells expressing
LacZ in L6 myotubes (Fig. 3D), whereas the activity could not
be detected in 3T3L-1 adipocytes, even at the basal state (data
not shown). Moreover, expression of GSK3a resulted in a de-
crease in basal GS activity (about 30%) in 3T3L-1 adipocytes
compared with cells expressing LacZ, consistent with the re-
sults in 293 cells (40), whereas such suppression of GS activity
was not observed in cells coexpressing GSK3 and GagPKB (Fig.
3E). From these data, we conclude that PKB stimulates GS
activity by regulating GSK3 activity in L6 myotubes. Our data
FIG. 3. Expression of GagPKB increases GS activity in L6 myotubes via inhibition of GSK3 activity, but does not affect GS activity
in 3T3L-1 adipocytes. A, GS activity in 3T3L-1 adipocytes expressing the indicated constructs. Serum-starved cells were washed with KRHB and
pretreated without or with wortmannin for 30 min before being treated without or with 100 nM insulin for 20 min. Cells were then lysed and
subjected to assay of GS activity as described under “Experimental Procedures.” Each result was converted to the activity ratio determined by
dividing the activity measured with 0.25 mM glucose 6-phosphate (ligand-dependent activity) by the activity measured with 10 mM glucose
6-phosphate (total activity). The activity ratio in untreated 3T3L-1 cells expressing LacZ was 0.23 6 0.04. B, GS activity in L6 myotubes expressing
the indicated constructs. Cells were treated and subjected to the assays as described above. The activity ratio in untreated L6 cells expressing LacZ
was 0.06 6 0.01. The results in A and B are expressed as the ratio to the value of untreated cells expressing LacZ. Each bar represents the mean 6
S.E. of more than three independent experiments. C, detection of PP1G and GSK3 in 3T3L-1 adipocytes and L6 myotubes. Cell lysates containing
30 mg of protein were subjected to SDS-polyacrylamide gel electrophoresis followed by Western blot analysis with anti-PP1G antibodies (7% gel),
anti-GSK3a antibodies, or anti-GSK3b antibodies (10% gel). D, inhibition of GSK3 kinase activity by insulin or expression of GagPKB.
Serum-starved cells were treated without or with 100 nM insulin for 10 min. Cells were immunoprecipitated with anti-GSK3a antibody, and the
immunoprecipitates were subjected to determination of kinase activity, as described under “Experimental Procedures.” The results are expressed
as per cent of maximum to the value of untreated cells expressing LacZ. Each bar represents the mean 6 S.E. of more than three independent
experiments. E, GS activity in 3T3L-1 adipocytes affected by expression of GSK3 or both GSK3 and GagPKB. Cells were cultured and infected with
adenoviruses as described under “Experimental Procedures” then lysed and subjected to SDS-polyacrylamide gel electrophoresis (10% gel) followed
by Western blotting with aPKB-CT or 12CA5 (upper panels). GS activity in untreated cells expressing the indicated constructs was measured
(lower panel). The activity ratio in cells expressing LacZ was 0.21 6 0.03. The results are expressed as the ratio to the value of cells expressing LacZ.
Each bar represents the mean 6 S.E. of more than three independent experiments.
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also suggested that regulation of GS activity by PP1G via
PI3-K, independent of PKB, might be dominant in 3T3L-1
adipocytes. This may explain the lack of stimulation of glyco-
gen synthesis by a constitutively active PKB in 3T3L-1 adipo-
cytes (this study and Ref. 25). Taken together, these findings
suggested the possibility that PKB might act as a key regulator
in glycogen synthesis in skeletal muscle. Recent studies have
demonstrated that GSK3 is detected, and the kinase activity is
negatively regulated by insulin in isolated fat cells (42, 43),
different from the results with 3T3L-1 adipocytes shown in this
study. It suggests the possibility that PKB/GSK3 signaling
pathway in adipose tissue might be also involved in the regu-
lation of glycogen synthesis in vivo.
Activation of PKB Mimics Insulin-induced Protein Synthesis
both in 3T3L-1 Adipocytes and L6 Myotubes—The stimulation
of protein synthesis is an important and early response by
insulin and is observed in a wide variety of cell types (44). The
initiation phase of translation is rate-limiting, and the regula-
tion by insulin is exerted at this step. The most important event
is phosphorylation of 4E-BP1 (PHAS-I) in response to insulin
and its dissociation from eIF-4E/4E-BP1 complex, leading to
mRNA translation. MAPK was reported to phosphorylate 4E-
BP1 in vitro and to abolish binding of 4E-BP1 to eIF-4E (10).
However, recent studies revealed that insulin promotes the
phosphorylation of multiple sites in 4E-BP1, one of which is
likely to involve PI3-K-p70 S6 kinase, since it occurs in a
rapamycin-sensitive and MAPK-independent manner (33, 45–
48). 4E-BP1 detected by Western blot appears as three bands,
designated a, b, and g, representing different extents of phos-
phorylation in 3T3L-1 adipocytes (Fig. 4A), as described (36).
Indeed, wortmannin inhibited the increase in the amount of g
band in response to insulin, but expression of DNRas did not
alter phosphorylation levels of 4E-BP1 (Fig. 4A), suggesting
that such phosphorylation by insulin is PI3-K-dependent and
MAPK-independent. We next investigated the effect of Gag-
PKB, a putative regulatory molecule of downstream effectors of
PI3-K such as p70 S6 kinase, on phosphorylation of 4E-BP1
and protein synthesis in response to insulin in both cell lines.
Expression of GagPKB resulted in much higher phosphoryla-
tion of 4E-BP1 in basal and insulin-stimulated states. In cells
expressing GagPKB, the basal levels of phosphorylation of
4E-BP1 were much higher than in cells expressing LacZ, even
after treatment with wortmannin (Fig. 4B), suggesting that
GagPKB can stimulate 4E-BP1 phosphorylation downstream
of PI3-K. In L6 myotubes, essentially the same results were
observed (data not shown). These data suggested that activa-
FIG. 4. The effect of expression of GagPKB on phosphorylation of 4E-BP1 and protein synthesis. A, inhibition of phosphorylation of
4E-BP1 by wortmannin but not by DNRas in 3T3L-1 adipocytes. B, the effect of expression of GagPKB on phosphorylation of 4E-BP1 in 3T3L-1
adipocytes. Serum-starved cells were pretreated without or with wortmannin (30 nM) then treated without or with 100 nM insulin for 15 min, lysed,
and subjected to Western blot analysis by anti-4E-BP1 antibodies (13% gel). C, the effect of expression of GagPKB on the incorporation of
[3H]tyrosine into protein. Serum-starved cells were subjected to determination of protein synthesis rate as described under “Experimental
Procedures.” The results are expressed as the ratio to the value of untreated cells expressing LacZ. Each bar represents the mean 6 S.E. of more
than three independent experiments.
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tion of PKB might promote protein synthesis by phosphoryl-
ating 4E-BP1. Expression of GagPKB indeed increased the
protein synthesis rate in both cell lines (Fig. 4C). Recently, a
hypothetical model for the pathways promoting phosphoryla-
tion of 4E-BP1 in response to insulin has been proposed (46, 48,
49). According to this model, insulin stimulates phosphoryla-
tion on multiple sites of 4E-BP1 that might be mediated by the
putative proline-directed serine/threonine kinase. Rapamycin
potently inhibits this serine/threonine kinase, thereby inhibit-
ing phosphorylation of both 4E-BP1 and p70 S6 kinase. (Very
recently, Brunn et al. (50)) has demonstrated that TOR (target
of rapamycin) may, in fact, directly phosphorylate PHAS-I.)
Since expression of GagPKB stimulated 4E-BP1 phosphoryla-
tion and p70 S6 kinase activity, which were both inhibited by
rapamycin in cells expressing LacZ (data not shown), PKB may
activate the common kinase downstream of PI3-K, phosphoryl-
ating both 4E-BP1 and p70 S6 kinase in a TOR-sensitive fash-
ion; phosphorylation of 4E-BP1 and phosphorylation and acti-
vation of p70 S6 kinase could cause a rise in cap-dependent
mRNA translation and phosphorylation of ribosomal S6 pro-
tein, respectively, leading to increased protein synthesis.
Skeletal muscle is the primary site for insulin-stimulated
glucose uptake, and a large part of the glucose incorporated
into muscle cells is deposited as glycogen in response to insulin
(51, 52). Thus, glucose uptake and glycogen synthesis in skel-
etal muscle play a pivotal role in blood glucose homeostasis in
human. Protein synthesis is also promoted by insulin, predom-
inantly in skeletal muscle (36, 53). Numerous reports have
suggested the physiological role of PI3-K in these three most
important biological effects of insulin (11–17, 33, 46–48). How-
ever, the molecular mechanisms downstream of PI3-K remain
unclear. Our report provides the first evidence that PKB activ-
ity is sufficient to activate glucose uptake, glycogen synthesis,
and protein synthesis in vivo in L6 myotubes, suggesting the
possibility that PKB might regulate these three major biologi-
cal responses to insulin in skeletal muscle. Our data also re-
vealed that PKB might be the molecular link between PI3-K
and these biological effects by insulin. However, they do not
rule out either the possible role of other PKB-independent
pathways or the importance of cooperation with other mole-
cules such as PI3-K. Indeed, platelet-derived growth factor
(PDGF) as well as insulin does activate PKB (18, 19). However,
PDGF almost never affects glucose metabolism and is generally
believed not to mediate significant stimulation of GLUT4
translocation, although overexpression of PDGF receptor was
reported to promote GLUT4 translocation by PDGF in Chinese
hamster ovary cells (54). With respect to glucose transport,
translocation of PI3-K to the target such as GLUT4 vesicle in
response to insulin has been reported to occur but not to PDGF
(55, 56). Thus, in the case of PKB, targeting to the same
compartment as PI3-K might be necessary for these biological
effects by insulin. In fact, GagPKB is mainly localized in the
plasma membrane, low density microsomal membrane, and
high density microsomal membrane. This subcellular distribu-
tion is similar to that of p85 subunit of PI3-K (38) and might
make it possible for GagPKB to mimic the biological actions of
insulin. However, our data do not imply that all the down-
stream actions of PI3-K are mediated by PKB. For instance,
expression of GagPKB did not affect thymidine incorporation
into DNA in 3T3L-1 adipocytes,2 whereas expression of consti-
tutively active PI3-K promoted that in those cells (17), suggest-
ing that signals downstream of PI3-K diverge into at least two
pathways; PKB-dependent and -independent.
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